



Research Article

Estimation of Fesoterodine fumarate in tablet dosage forms by a new RP-HPLC method

Tentu. Nageswara Rao*¹, G. Suresh², Dr. K. Raghu babu¹ and E.G. Sreenivasula Reddy³

¹Department of Engineering Chemistry, Andhra University, Visakhapatnam, AP, India.

²Department of Chemistry, GITAM University, Visakhapatnam, AP, India.

³SK University, Anantapur, AP, India.

(Received: 30 July, 2012; Accepted: 03 August, 2012; Published: 29 August, 2012)

*Corresponding Author: Email: tentu6581@rediffmail.com

ABSTRACT

A Simple, Sensitive and specific reverse phase high performance liquid chromatographic method has been developed for the determination of Fesoterodine fumarate in tablet Dosage forms. Chromatographic separation was achieved on a Phenomenex, C18 (250×4.6 mm), 5.0 μm column with a 49.5:0.5:50 mixture of 0.025M ammonium dihydrogen phosphate w/v, triethylamine v/v and acetonitrile v/v, Then adjusted the pH to 7.0 with dilute ortho phosphoric acid as mobile phase, detection was at 225 nm. Response was a linear function of concentration in the range 2-0.01 μg/mL for Fesoterodine fumarate. LOD and LOQ for Fesoterodine fumarate were found 0.01 μg/mL and 0.03 μg/mL. Accuracy (recoveries 90-97%) and reproducibility were found to satisfactory.

Key words: Fesoterodine fumarate, RP-HPLC method, method validation.

INTRODUCTION

Fesoterodine fumarate (Figure 1) is a competitive muscarinic receptor antagonist. Muscarinic receptors play role in contractions of urinary bladder smooth muscle and stimulation of salivary secretion. Fesoterodine fumarate specifically indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Chemically, fesoterodine fumarate^{3,4} is designated as isobutyric acid 2-((R)-3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl) phenyl ester hydrogen fumarate.

In this paper we describe a simple, sensitive, and validated RP-HPLC method for determination of Fesoterodine fumarate^{1,2} in tablet Dosage Forms. The method has been successfully used for quality control analysis of the drugs and other analytical purposes.




Figure 1: The structure of Fesoterodine fumarate

APPARATUS AND CHROMATOGRAPHIC CONDITIONS

Chromatographic separation was performed on a Shimadzu chromatographic system equipped with a LC-20AT pump and SPD-20A UV-VIS detector with 20 μL fixed loop and analyzed by using LC-Solution software.

Phenomenex C18 (250×4.6 mm), 5.0 μm column with a 49.5:0.5:50 mixture of 0.025M ammonium dihydrogen phosphate w/v, triethylamine v/v and acetonitrile v/v, Then adjusted the pH to 7.0 with dilute ortho phosphoric acid as mobile phase was delivered at flow rate 1.2 mL/min. The mobile phase was filtered through 0.45 μm membrane filter and sonicated for 10 min. An external standard method was used. UV detection was performed at 225 nm and column oven temperature is 35°C. Peak was confirmed by comparison of retention time with standard.

REAGENTS AND SOLUTIONS

Preparation of standard solution

Accurately weighed 4.03 mg of reference standard of Fesoterodine fumarate in 100ml volumetric flask and the volume was brought upto the mark using acetonitrile.

Preparation of sample solution

The commercial samples of tablet containing the drug namely toviaz, 4 mg (Pfizer) chosen for this purpose. One tablet, containing 4 mg of Fesoterodine fumarate was weighed accurately and transferred to a 100 ml volumetric flask with 30ml acetonitrile, shaken for 5min, then diluted to volume with acetonitrile to furnish a solution containing 40 µg/mL Fesoterodine fumarate. After filtration the solution the solution was diluted with diluent as an acetonitrile to give a final concentration of 1 µg/mL Fesoterodine fumarate.

METHOD VALIDATION

Once the HPLC method development was over, the method was validated in terms of parameters like specificity, precision, accuracy, linearity and range, LOD, LOQ, ruggedness, robustness, stability etc. For all the parameters percentage relative standard deviation values were calculated. The proposed HPLC method was validated as per ICH guidelines⁶.

Linearity and range

Different known concentrations of Fesoterodine fumarate (2.0 µg/mL – 0.01 µg/mL) were prepared in diluent by diluting the stock solution. Injected the standard solutions and measured the peak area. A calibration curve has been plotted for concentration of the standards injected versus area observed and the linearity of the method was determined from the correlation coefficient. The results were shown in Table: 2. the slope, intercept and correlation coefficient values were found to be 14051, 98.23 and 0.9999.

Precision

Precision was evaluated by carrying out three independent sample preparation of a single lot of formulation. The sample solution was prepared in the same manner as described in the sample preparation. Percentage relative standard deviation (% RSD) was found to be less than 1% for within a day and day to day variations, which proves that that method is precise. Results were shown in Table 3-4.

Accuracy

To study the reliability, suitability and accuracy of the method recovery experiments were carried out. A known quantity of the pure drug was added to the preanalysed sample formulation at the level of 50%, 100% and 200%, dissolved in diluents and made up to 100ml with same solvent. Further dilutions were made so that the each aliquot contained 0.03mg/L of Fesoterodine fumarate. The contents were determined from the respective chromatograms. The concentration of the drug product in the solution was determined using assay

method. The recovery procedure was repeated 10 times and % RSD was calculated by using the following formula. The contents of Fesoterodine fumarate tablet found by proposed method are shown in Table 3; the lower values of RSD of assay indicate the method is accurate⁵. The mean recoveries were in range of 90-97 % which shows that there is no interference from excipients. (Table: 5)

$$\% \text{ recovery} = \frac{b-a}{c}$$

Where,

- a-The amount of drug found before the addition of standard drug
- b-The amount of drug found after the addition of standard drug
- c- The amount of standard drug added

Repeatability of solution

A standard solution of drug substance was injected ten times and corresponding peak areas were recorded. The % RSD was found to be less than 1%. (Table:6.)

Specificity

Condition of HPLC method like percentage of organic solvent in mobile phase, ionic strength, pH of buffer flow rate etc, was changed. In spite of above changes no additional peaks were found, although there were shift retention times or little changes in peaks shapes.

Assay

20µl of standard and sample solutions were injected into an injector of RP-HPLC, from the peak area of standard amount of drug in sample were computed. The values are given in Table: 7.

Limit of detection and limit of quantification

The limit of Detection (LOD) and limit of Quantification (LOQ) of the development method were determined by injecting progressively low concentrations of the standard solutions using the developed RP-HPLC method. The LOD is the smallest concentration of the analyte that gives a measurable response (signal to noise ratio of 3). The LOD for Fesoterodine fumarate found to be 0.01µg/mL The LOQ is the smallest concentration of the analyte, which gives response that can be accurately quantified (signal to noise ratio of 10) The LOQ was 0.03 µg/mL for Fesoterodine fumarate. It was concluded that the developed method is sensitive.

Ruggedness and robustness

The ruggedness of the method was determined by carrying out the experiment on different instruments like shimadzu HPLC and Agilent

HPLC by different operators using different columns of similar types. The %RSD values with two different instruments Shimadzu HPLC and Agilent HPLC, analyst and columns were 0.5-0.5, 0.6-0.5 and 0.4-0.3% respectively.

Robustness of the method was determined by making slight changes in the chromatographic conditions, such as changes in mobile phase, flow rate and column temperature. It was observed that there were no marked changes in the

chromatograms, which demonstrated that the RP-HPLC method is rugged and robust. The robustness limit for mobile phase variation, flow rate variation, and temperature variation are well within the limit, which shows that the method is having good system suitability and precision under given set of conditions and were within the acceptance criteria of not more than 2%.




Figure 2: Chromatogram of standard (1.0 µg/mL)

RESULTS AND DISCUSSION

UV spectrum of Fesoterodine fumarate was recorded from which 225 nm was selected as wavelength. Flow rate of 1.2 mL/min was selected. 49.5:0.5:50 mixture of 0.025M ammonium dihydrogen phosphate w/v, triethylamine v/v and acetonitrile v/v, then adjusted the pH to 7.0 with dilute ortho phosphoric acid as mobile phase. The retention time was found to be 5.4 min. Fesoterodine fumarate shown linearity in the range

of 0.01-2 µg/mL, and the co-efficient was found to be 0.9999. Recovery studies were performed at 50%, 100% and 200%, levels. The sensitivity of method LOD and LOQ is shown in Table 2. The stability at room temperature and refrigeration was found to be 3 and 8.5 hrs respectively. Hence the proposed method is simple, accurate, and rapid and can be employed for routine analysis. The low standard deviation and good percentage recovery indicates the reproducibility and accuracy of the method.




Figure 3 Linearity curve of Fesoterodine fumarate

Regression analysis of the calibration curve for Fesoterodine fumarate showed a linear relationship between the concentration and peak area with

correlation coefficients higher than 0.9999 in all curves assayed.

Table1: Optimized chromatographic conditions

Parameter	Optimized condition
Chromatograph	HPLC (Shimadzu system equipped with LC-20 AT pump and SPD-20A interfaced with LC Solution software)
Column	Phenomenex C18 (250×4.6 mm), 5.0 µm column
Mobile Phase	49.5:0.5:50 mixture of 0.025M ammonium dihydrogen phosphate w/v, triethylamine v/v and acetonitrile v/v, Then adjusted the pH to 7.0 with dilute ortho phosphoric acid
Flow Rate	1.2 mL/min
Detection	UV at 225 nm
Injection Volume	20µL
Column oven temperature	35°C

Table 2: Validation Parameters

Parameters	Fesoterodine fumarate
Linearity range	0.01-2 µg/mL
Correlation coefficient	0.9999
Slope	14051
Y Intercept	98.23

Table 3: Intraday Precession

Concentration (µg/mL)	Area	%RSD
0.03	557	1.10
	549	
	544	
0.3	5362	0.93
	5412	
	5463	
1	14132	0.82
	14006	
	14236	

The intraday precision was found to be within 1% RSD for conc.0.03, 0.3, 1.0µg/mL

Table 4: Interday Precision

Concentration (µg/mL)	Day	Area	% RSD
0.03	1	502	1.58
	2	512	
	3	518	
0.3	1	5164	1.33
	2	5029	
	3	5106	
1	1	13815	1.02
	2	13774	
	3	14036	

Intraday precision was performed for con. Of 0.03, 0.3 and 1.0 µg/mL For about three days and their

peak, areas are shown in the table. The %RSD for within 2%
con. 0.03, 0.3, and 1.0 µg/mL was found to be

Table 5: Recovery studies

Level (µg/mL)	% Recovery	% RSD
0.03	91	0.98
0.3	96	0.79

Recovery studies were performed at 0.03 µg/mL and 0.3 µg/mL levels and the results were found to be within the limits mentioned as per ICH guidelines.

Table 6: Repeatability of injection

Con (mg/L)	Peak area	%RSD
0.3	5202	1.21
	5167	
	5226	
	5301	
	5179	
	5291	
	5342	
	5162	
	5181	
	5213	

Repeatability of injection was performed using 0.3 µg/mL sample for 10 times and corresponding peak areas were recorded. The % RSD peak was reported.

Table 7: Analysis of formulation

Amount of drug (mg)		% Label claim	%RSD (n=6)
Labeled	Estimated	95	0.59
4	3.81		

Analysis of formulation was performed using Fesoterodine fumarate 4 mg of tablet and the claim was found to be 95.

CONCLUSION

A convenient and rapid RP-HPLC method has been developed for estimation of Fesoterodine fumarate in tablet dosage form. The assay provides a linear response across a wide range of concentrations. Low intra-day and inter-day % RSD coupled with excellent recoveries. The proposed method is simple, fast, accurate and precise for the simultaneous quantification of Fesoterodine fumarate in dosage form, bulk drugs as well as for routine analysis in quality control.

ACKNOWLEDGEMENT

The authors are thankful to Mr. Naresh, Micro labs Ltd for his keen interest and help.

REFERENCES

1. Sangoi MS, Steppe M. Determination of Fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry, *Eur J Mass Spectrom*, **2010**; 16(6): 653-661.
2. Sangoi MS, Todeschini V, Steppe M. Fesoterodine stress degradation behavior by liquid chromatography coupled ultraviolet detection and electrospray ionization mass spectrometry, *Talanta*, **2011**; 84(4): 1068-79.
3. Chapple CR, Van Kerrebroeck PE, Junemann KP, Wang JT, Brodsky M. Comparison of

fesoterodine and tolterodine in patients with overactive bladder, *BJU International*, **2008**.

4. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life, *BJU International*., **2008**;102(1): 56-61.
5. The British Pharmacopoeia. British Pharmacopoeial Commission, London, UK, **2008**.
6. I.C.H Guidelines. Analytical Method Validation (Q3) Geneva, **2000**.